Innography Releases Three High-Value Professional Service Offerings

AUSTIN, Texas, Jul 09, 2014 (BUSINESS WIRE) --Innography , the innovative software provider of better intellectual property answers for improved business results, today announces three brand new consulting service offerings powered by the firm’s industry-leading IP analytics platform, Innography Advanced Analysis . The innovative professional services include the IP Due Diligence Report, the License Candidate Identification analysis and the IP Maturity Model Assessment.

“Innography’s latest three packaged service offerings give patent owners unique insights into their intellectual property portfolios and opportunities,” said John F. Martin, chief executive officer and chairman of Innography. “By leveraging our best-of-breed corrected patent data and proprietary analytics, these services help clients quickly determine possibilities and risks when making important patent-related decisions.”

http://www.marketwatch.com/story/innography-releases-three-high-value-professional-service-offerings-2014-07-09

India: Patent Counter Claim And Revocation Petition Cannot Be Pursued Simultaneously: SC

• The Supreme Court in this decision has indicated its desire to avoid multiplicity of proceedings on the same issue before different forums.
• Post grant opposition of a patent initiated by any person interested, will abate the right of the same person to file a revocation petition or a counter claim of revocation of the same patent.
• The revocation petition of patent and counter claim of revocation of patent in an infringement suit cannot be availed as simultaneous remedy.

http://www.mondaq.com/india/x/324912/Patent/PATENT+COUNTER+CLAIM+AND+REVOCATION+PETITION+CANNOT+BE+PURSUED+SIMULTANEOUSLY+SC

NY firm sues Aurobindo for Alzheimer’s generic drug

New York-based Forest Laboratories has sued Indian generics firm Aurobindo Pharma for intending to make a similar version of patented drug Namenda, used to treat Alzheimer’s.

The case filed on June 27 alleges infringement of patent No. 5,061,703 titled 'Adamantane derivatives in the prevention and treatment of cerebral ischemia' which was granted by the US patent and trademark office in June 2007. While Frankfurt-based Merz pharma is the owner of the patent, the exclusive licensee is Forest Laboratories.

Aurobindo had subm­itted an abbreviated new dr­ug application (ANDA) to FDA seeking approval to make and market a generic version of the drug around mid-May. The 703 patent expires in April 2015.

Forest Laboratories has sought Delaware district court’s intervention to prevent Aurobindo selling this drug before the expiry of the patent, including exclusivities and extensions. It also wants monetary relief from the Indian company. Reports suggest that in the last quarter of 2013, Namenda had sales of $379.2 million, while Namenda XR logged $37.8 million.

The Forest website says the company plans to discontinue the sale of Namenda 5 mg and 10 mg tablets in fall 2014. “This action is not due to any safety or efficacy issue related to Namenda tablets. The oral solution of Namenda will continue to be available, along with Namenda XR (memantine HCl) extended-release capsules. This drug is for the treatment of moderate to severe dementia of the Alzheimer’s type. Namenda, a twice daily immediate release formulation, was approved in October 2003."

Source and Full News:
http://www.mydigitalfc.com/news/ny-firm-sues-aurobindo-alzheimer%E2%80%99s-generic-drug-008

Will India Be the Uber of the Pharmaceutical Industry?

http://truth-out.org/opinion/item/24670-will-india-be-the-uber-of-the-pharmaceutical-industry

Many self-styled libertarians have been celebrating the rise of Uber. Their story is that Uber is a dynamic start-up that has managed to disrupt the moribund cab industry. The company now has a market capitalization of $17 billion.

While Uber's market value probably depends mostly on its ability to evade the regulations that are imposed on its competitors, the company has succeeded in transforming the industry. At the least we are likely to see a modernized regulatory structure that doesn't saddle cabs with needless regulations and fees.

Unfortunately, the taxi industry is not the only sector of the U.S. economy that can use modernization. The pharmaceutical industry makes the taxi industry look like cutting edge social media. The government imposed barriers to entry in the pharmaceutical industry don't just raise prices by 20 or 30 percent, as may be the case with taxi fares, they raise prices by a factor or ten, twenty, or even one hundred (that would be 10,000 percent).